As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors.

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.